Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
APOE ε4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease.
|
31791659 |
2020 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These studies suggest that modulating VEGFR-1 expression and signaling events could potentially prevent senescence and rejuvenate EC functions, and provides us with a novel target to pursue for prevention and treatment of cerebrovascular dysfunction in AD.-Angom, R. S., Wang, Y., Wang, E., Pal, K., Bhattacharya, S., Watzlawik, J. O., Rosenberry, T. L., Das, P., Mukhopadhyay, D. VEGF receptor-1 modulates amyloid β 1-42 oligomer-induced senescence in brain endothelial cells.
|
30576228 |
2019 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study explored associations between brain expression of VEGF genes with cognitive performance and AD pathology.
|
31332262 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These observations provide a novel implication for VEGF as a therapeutic approach for the treatment of AD.
|
29702127 |
2019 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, we found genes that encode proteins with neuroprotective function (14-3-3 proteins, PIN1, ATXN1, BDNF, VEGFA) to be part of the downregulated AD subnetwork.
|
29875655 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathway-enrichment analysis for the possible regulatory targets indicated that vascular endothelial growth factor (VEGF) and VEGF-receptor signaling were pivotal in the treatment of AD with FQD.
|
30519025 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have investigated whether altered expression of VEGF receptors might account for the lack of angiogenic response to VEGF in AD.
|
29226875 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study suggests that VEGF levels in the CSF do not reflect the cerebral vascular alterations in either AD or VaD patients.
|
29933741 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that VEGF levels were associated with cerebral glucose metabolism in patients with mild cognitive impairment (MCI) and AD, but not in cognitively normal older adults.
|
30278247 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In CSF, random effects meta-analysis showed significantly deceased BDNF and increased NGF levels in patients with AD, whereas IGF and VEGF did not show significant differences between the AD group and control group.
|
29956088 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings support the notion that VEGF constitutes a relevant molecular target to be further explored in AD pathology and therapy.
|
29710700 |
2018 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A common polymorphism in the VEGF gene (-2578 C/A) is associated with circulating VEGF levels, cancers and Alzheimer's disease.
|
28402004 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A large panel of inflammatory cytokines (interleukin [IL]-1β, IL-1ra, IL-2, IL-4, IL-6, IL-10, IL-17, interferon-γ, tumor necrosis factor-α, and vascular endothelial growth factor) was analyzed using a multiplex immunoassay in 27 patients with a diagnosis of AD dementia and in 18 control subjects.
|
28719891 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma levels of VEGF in patients with AD were higher than those in healthy control subjects.
|
29255164 |
2017 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
|
28356047 |
2017 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, HK532-IGF-I cells preferentially differentiate into gamma-aminobutyric acid-ergic neurons, a subtype dysregulated in AD; produce increased vascular endothelial growth factor levels; and display an increased neuroprotective capacity in vitro.
|
26744412 |
2016 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These animal model findings suggest that the VEGF system is a promising target for the treatment of apoE4 carriers in AD.
|
27372644 |
2016 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, PLGA-VEGF nanospheres may be a potential strategy to modulate proliferative neuronal progenitors in the hippocampal region, and therefore, provide new insight for future therapeutic approaches in AD.
|
26502822 |
2015 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The excess vascular endothelial growth factor (VEGF) produced in the Alzheimer's disease (AD) brain can harm neurons, blood vessels, and other components of the neurovascular units (NVUs).
|
24948534 |
2014 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we performed a meta-analysis of observational studies to explore the association between polymorphisms in the VEGF gene promoter and AD risk.
|
23575378 |
2013 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to genetic studies, Alzheimer's disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin-angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate.
|
23689075 |
2013 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Conclusively, the result of this meta-analysis suggested that VEGF promoter polymorphisms (-2578C/A, -1154G/A) might not contribute to the susceptibility of AD.
|
23370341 |
2013 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The distribution of genotype and allele frequencies of the VEGF (-2578C/A) and (-1154G/A) polymorphisms did not differ significantly between AD and control groups (p>0.05).
|
20138124 |
2010 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To further evaluate these findings, we genotyped two SNPs in the VEGF gene (rs699947 [-2578]) and rs1570360 [-1154]) by TaqMan Allelic Discrimination in a study sample including AD patients (n = 801) and controls (n = 286).
|
19842071 |
2010 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stereologically-implanted encapsulated VEGF-secreting cells could offer an alternative strategy in the treatment of AD.
|
20430437 |
2010 |